Victory Square Technologies secures a key U.S. patent for Insu Therapeutics, enhancing the commercial potential of its InsuTab and BuccaGLP platforms while strengthening distribution ties with Hydreight Technologies.
The U.S. patent allowance serves as a critical milestone for Insu Therapeutics, solidifying the intellectual property foundation for its flagship products, InsuTab and BuccaGLP. This regulatory progress, combined with existing distribution agreements, positions the company to advance its commercialization strategy.
The patent foundation specifically supports the development and commercialization of InsuTab and BuccaGLP.
Victory Square Technologies is positively impacted by the U.S. patent allowance granted to its portfolio company, Insu Therapeutics. This development strengthens the overall intellectual property portfolio of Victory Square and validates the commercial potential of the InsuTab and BuccaGLP platforms.
It secures the intellectual property foundation for key assets InsuTab and BuccaGLP, enhancing the value of Victory Square's portfolio.
Hydreight's previously disclosed U.S. distribution rights for Insu Therapeutics' products become more valuable with the patent allowance.
Victory Square Technologies announced a significant U.S. patent allowance for its portfolio company, Insu Therapeutics. This development strengthens the intellectual property foundation for the InsuTab and BuccaGLP platforms, bolstering the value of Hydreight Technologies' existing U.S. distribution rights.
The patent allowance strengthens the intellectual-property foundation for Insu Therapeutics' core products, InsuTab and BuccaGLP, providing a more secure commercial position.
Hydreight Technologies holds exclusive U.S. distribution rights for Insu Therapeutics' products, which become more valuable as the underlying intellectual property is solidified.